(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are VIVORYON, NX FILTRATION, and DGB GROUP N.V..

Financial Asset	Price	Change	Updated (EST)
VIVORYON (VVY.AS)	1.77	26.83%	2024-06-27 12:04:39
NX FILTRATION (NXFIL.AS)	4.81	16.65%	2024-06-27 12:03:18
DGB GROUP N.V. (DGB.AS)	0.96	12.94%	2024-06-27 12:01:39
ADOCIA (ADOC.PA)	9.14	12.02%	2024-06-27 12:45:09
TEKNA HOLDING (TEKNA.OL)	5.72	7.12%	2024-06-27 12:44:02
ODFJELL SER. B (ODFB.OL)	158.00	6.04%	2024-06-27 12:41:53
CELYAD ONCOLOGY (CYAD.BR)	0.29	6.02%	2024-06-27 12:05:43
BELSHIPS (BELCO.OL)	25.30	5.86%	2024-06-27 12:25:06
ODFJELL SER. A (ODF.OL)	177.60	5.84%	2024-06-27 12:41:51
ATOS (ATO.PA)	1.18	5.49%	2024-06-27 12:46:12

The three biggest losers today are GLINTT, LAVIDE HOLDING, and KEYWARE TECH..

Financial Asset	Price	Change	Updated (EST)
GLINTT (GLINT.LS)	0.45	-9.6%	2024-06-27 12:23:22
LAVIDE HOLDING (LVIDE.AS)	0.25	-9.09%	2024-06-27 12:02:53
KEYWARE TECH. (KEYW.BR)	0.72	-8.86%	2024-06-27 12:20:32
BENFICA (SLBEN.LS)	3.10	-6.06%	2024-06-27 12:23:04
NYXOAH (NYXH.BR)	6.66	-5.93%	2024-06-27 12:20:56
FLUXYS BELGIUM D (FLUX.BR)	16.00	-5.6%	2024-06-27 12:06:25
ALAN ALLMAN (AAA.PA)	7.90	-5.39%	2024-06-27 12:45:30
PCI BIOTECH HOLD (PCIB.OL)	1.83	-3.68%	2024-06-27 12:42:11
RAMADA (RAM.LS)	6.30	-3.67%	2024-06-27 12:23:51
BERGENBIO (BGBIO.OL)	11.90	-3.6%	2024-06-27 12:25:08

Winners today

1. VIVORYON (VVY.AS)

26.83% Price Change

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

AEX-Index ended the session with VIVORYON rising 26.83% to €1.77 on Thursday, after five successive sessions in a row of losses. AEX-Index rose 0.21% to €925.11, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.

More news about VIVORYON.

2. NX FILTRATION (NXFIL.AS)

16.65% Price Change

NX Filtration N.V. develops, manufactures, and sells hollow fiber membrane modules in Netherlands, Europe, North America, Asia, and internationally. The company offers direct nanofiltration, ultrafiltration, and microfiltration membrane modules that remove bacteria, viruses, micropollutants, color, and selective salts from water without pre-treatment and use of chemicals. It provides HYDRAcap ultrafiltration modules to treat surface water, ground water, sedawater, and wastewaters as pretreatment to reverse osmosis and nanofiltration; and Projection Tool, and intuitive and online platform that enables the rapid and iterative system design for dNF membranes. In addition, the company offers integrated rack design and testing and piloting services. The company was incorporated in 2016 and is headquartered in Enschede, the Netherlands.

AEX-Index ended the session with NX FILTRATION rising 16.65% to €4.81 on Thursday, after four successive sessions in a row of losses. AEX-Index rose 0.21% to €925.11, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, NX FILTRATION has a trailing twelve months EPS of €-0.47.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.78%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NX FILTRATION’s stock is considered to be overbought (>=80).

Volatility

NX FILTRATION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.41%, a negative 0.56%, and a positive 3.92%.

NX FILTRATION’s highest amplitude of average volatility was 2.41% (last week), 4.06% (last month), and 3.92% (last quarter).

Moving Average

NX FILTRATION’s value is way higher than its 50-day moving average of €4.00 and under its 200-day moving average of €4.97.

Volume

Today’s last reported volume for NX FILTRATION is 103627 which is 58.87% below its average volume of 252009.

More news about NX FILTRATION.

3. DGB GROUP N.V. (DGB.AS)

12.94% Price Change

DGB Group N.V. invests in, develops, and manages carbon credits and biodiversity projects for businesses and governments in the Netherlands and internationally. The company offers nature-based solutions comprising removing or avoiding carbon emissions, tackling social, and environmental challenges; manages projects that focuses on ecosystem restoration, habitat conservation, and biodiversity enrichment; and undertakes plastic projects, which consists of removing and recycling plastic, waste reduction, and environmental conservation works, as well as carbon offsetting projects for reducing carbon footprint of companies. It also provides ESG reporting and tree integration services. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 and is based in Haarlemmermeer, the Netherlands.

AEX-Index ended the session with DGB GROUP N.V. jumping 12.94% to €0.96 on Thursday, after three consecutive sessions in a row of gains. AEX-Index jumped 0.21% to €925.11, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.73%.

Moving Average

DGB GROUP N.V.’s value is way above its 50-day moving average of €0.60 and way above its 200-day moving average of €0.51.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DGB GROUP N.V.’s stock is considered to be oversold (<=20).

More news about DGB GROUP N.V..

4. ADOCIA (ADOC.PA)

12.02% Price Change

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

CAC 40 ended the session with ADOCIA rising 12.02% to €9.14 on Thursday, after two sequential sessions in a row of gains. CAC 40 dropped 1.03% to €7,530.72, after two sequential sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, ADOCIA has a trailing twelve months EPS of €-1.9.

Moving Average

ADOCIA’s worth is above its 50-day moving average of €9.07 and way higher than its 200-day moving average of €6.63.

Yearly Top and Bottom Value

ADOCIA’s stock is valued at €9.14 at 22:40 EST, way under its 52-week high of €16.16 and way higher than its 52-week low of €2.74.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ADOCIA’s stock is considered to be oversold (<=20).

Volatility

ADOCIA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.11%, a negative 0.51%, and a positive 3.03%.

ADOCIA’s highest amplitude of average volatility was 6.69% (last week), 3.66% (last month), and 3.03% (last quarter).

More news about ADOCIA.

5. TEKNA HOLDING (TEKNA.OL)

7.12% Price Change

Tekna Holding ASA engages in the development, manufacture, and sale of micron and nano powders, and plasma process solutions in North America, Europe, Asia, and internationally. The company offers spherical powders, such as titanium, nickel, and aluminum alloys, as well as tungsten and tantalum; and nanopowders, including nickel, silicon, and copper nanopowders, as well as boron nitride nanotubes for use in additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. It serves aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics industries. The company was founded in 1990 and is headquartered in Sherbrooke, Canada. Tekna Holding ASA is a subsidiary of Arendals Fossekompani ASA.

Oslo Børs Benchmark Index_GI ended the session with TEKNA HOLDING rising 7.12% to €5.72 on Thursday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.47% to €1,415.84, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-1.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.02%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 8%, now sitting on 40.14M for the twelve trailing months.

Moving Average

TEKNA HOLDING’s value is under its 50-day moving average of kr6.03 and way below its 200-day moving average of kr7.37.

More news about TEKNA HOLDING.

6. ODFJELL SER. B (ODFB.OL)

6.04% Price Change

Odfjell SE provides services for the transportation and storage of bulk liquid chemicals, acids, edible oils, and other specialty products in North America, South America, Norway, the Netherlands, rest of Europe, the Middle East, Asia, Africa, and Australasia. The company operates through Chemical Tankers and Tank Terminals segments. It owns and operates chemical tankers that offer global and regional transportation; and tank terminals, which provide storage of various chemical and petroleum products. As of December 31, 2023, it operated a chemical tanker fleet of 68 vessels, including 46 owned/leased, 5 operational bareboat, 14 time chartered, and 3 pool vessels. The company's terminal network consists of 459 tanks with 1.3 million cubic meters of storage capacity. Odfjell SE was incorporated in 1914 and is headquartered in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with ODFJELL SER. B rising 6.04% to €158.00 on Thursday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.47% to €1,415.84, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, ODFJELL SER. B has a trailing twelve months EPS of kr29.95.

PE Ratio

ODFJELL SER. B has a trailing twelve months price to earnings ratio of 5.28. Meaning, the purchaser of the share is investing kr5.28 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.93%.

Volatility

ODFJELL SER. B’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.57%, a negative 0.89%, and a positive 1.96%.

ODFJELL SER. B’s highest amplitude of average volatility was 2.40% (last week), 2.42% (last month), and 1.96% (last quarter).

More news about ODFJELL SER. B.

7. CELYAD ONCOLOGY (CYAD.BR)

6.02% Price Change

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with CELYAD ONCOLOGY jumping 6.02% to €0.29 on Thursday, after three sequential sessions in a row of losses. BEL 20 jumped 0.1% to €3,919.21, after two consecutive sessions in a row of losses, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.36.

More news about CELYAD ONCOLOGY.

8. BELSHIPS (BELCO.OL)

5.86% Price Change

Belships ASA owns and operates dry bulk ships worldwide. It operates through Belships and Lighthouse Navigation segments. The company operates a fleet of 38 modern Supra/Ultramax bulk carriers, including newbuildings. It also provides technical, crewing, port agency, and logistical services. The company was founded in 1918 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with BELSHIPS rising 5.86% to €25.30 on Thursday while Oslo Børs Benchmark Index_GI jumped 0.47% to €1,415.84.

Earnings Per Share

As for profitability, BELSHIPS has a trailing twelve months EPS of kr2.37.

PE Ratio

BELSHIPS has a trailing twelve months price to earnings ratio of 10.68. Meaning, the purchaser of the share is investing kr10.68 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 50.41%.

Volume

Today’s last reported volume for BELSHIPS is 307943 which is 24.16% below its average volume of 406086.

Sales Growth

BELSHIPS’s sales growth for the next quarter is negative 23.6%.

More news about BELSHIPS.

9. ODFJELL SER. A (ODF.OL)

5.84% Price Change

Oslo Børs Benchmark Index_GI ended the session with ODFJELL SER. A rising 5.84% to €177.60 on Thursday, after four consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 0.47% to €1,415.84, after two successive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, ODFJELL SER. A has a trailing twelve months EPS of kr29.95.

PE Ratio

ODFJELL SER. A has a trailing twelve months price to earnings ratio of 5.93. Meaning, the purchaser of the share is investing kr5.93 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.93%.

Yearly Top and Bottom Value

ODFJELL SER. A’s stock is valued at kr177.60 at 22:40 EST, way under its 52-week high of kr200.00 and way above its 52-week low of kr83.00.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.9%, now sitting on 1.2B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ODFJELL SER. A’s stock is considered to be oversold (<=20).

Volatility

ODFJELL SER. A’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.69%, a negative 0.55%, and a positive 1.94%.

ODFJELL SER. A’s highest amplitude of average volatility was 1.69% (last week), 2.29% (last month), and 1.94% (last quarter).

More news about ODFJELL SER. A.

10. ATOS (ATO.PA)

5.49% Price Change

Atos SE provides digital transformation solutions and services worldwide. It offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and Internet of things solutions; and modern applications and platforms. The company also provides advance detection and response, data protection and governance, digital workplace security, IoT and OT security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. It serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, and telecommunication and media industries. The company was incorporated in 1982 and is headquartered in Bezons, France.

CAC 40 ended the session with ATOS rising 5.49% to €1.18 on Thursday while CAC 40 dropped 1.03% to €7,530.72.

Earnings Per Share

As for profitability, ATOS has a trailing twelve months EPS of €-31.04.

Volume

Today’s last reported volume for ATOS is 2813810 which is 38.5% below its average volume of 4575520.

More news about ATOS.

Losers Today

1. GLINTT (GLINT.LS)

-9.6% Price Change

Glintt – Global Intelligent Technologies, S.A. provides IT consulting services for banking, insurance, public administration, and utilities sectors in Portugal, Spain, and Angola. It operates through two segments: Health and Other Markets. The company engages in the sale of equipment, furniture, consumables, and robotics solutions; development of architectural projects; and design and conception of lay-out and image for pharmacies, training, equipment maintenance, and consultancy projects. It licenses proprietary software solutions for healthcare providers, such as clinics, hospitals, pharmacies, and other bodies of the ministry of health; and develops, implements, and maintains software services for the health sector. In addition, the company implements ERPs, integrates internet systems, and develops tailor-made applications services. Further, the company develops, implements, and integrates partner platforms with emphasis on the BPM, ERP, BI and mobility solutions; and integrates IT infrastructures, as well as support for networking, security, storage systems, and database management. Glintt – Global Intelligent Technologies, S.A. was incorporated in 1995 and is based in Sintra, Portugal. Glintt – Global Intelligent Technologies, S.A. operates as a subsidiary of Farminveste – Investimentos, Participações E Gestão S.A.

PSI ended the session with GLINTT dropping 9.6% to €0.45 on Thursday, after two sequential sessions in a row of losses. PSI dropped 0.36% to €6,522.65, after two successive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.05.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 9.04. Meaning, the purchaser of the share is investing €9.04 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.11%.

Yearly Top and Bottom Value

GLINTT’s stock is valued at €0.45 at 22:40 EST, above its 52-week high of €0.42.

Volatility

GLINTT’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.02%, a positive 0.83%, and a positive 2.45%.

GLINTT’s highest amplitude of average volatility was 2.98% (last week), 2.69% (last month), and 2.45% (last quarter).

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 23, 2023, the estimated forward annual dividend rate is 0.02 and the estimated forward annual dividend yield is 4.78%.

More news about GLINTT.

2. LAVIDE HOLDING (LVIDE.AS)

-9.09% Price Change

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. is based in Amsterdam, the Netherlands.

AEX-Index ended the session with LAVIDE HOLDING dropping 9.09% to €0.25 on Thursday while AEX-Index jumped 0.21% to €925.11.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.02.

More news about LAVIDE HOLDING.

3. KEYWARE TECH. (KEYW.BR)

-8.86% Price Change

Keyware Technologies NV, an independent fintech company, provides electronic payments processing and management solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and payment processing and management services, as well as rents and sells payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.

BEL 20 ended the session with KEYWARE TECH. falling 8.86% to €0.72 on Thursday while BEL 20 jumped 0.1% to €3,919.21.

Earnings Per Share

As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.01.

PE Ratio

KEYWARE TECH. has a trailing twelve months price to earnings ratio of 72. Meaning, the purchaser of the share is investing €72 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.98%.

Volatility

KEYWARE TECH.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.69%, a negative 0.64%, and a positive 3.89%.

KEYWARE TECH.’s highest amplitude of average volatility was 2.11% (last week), 3.79% (last month), and 3.89% (last quarter).

Moving Average

KEYWARE TECH.’s worth is way under its 50-day moving average of €0.84 and way below its 200-day moving average of €0.90.

More news about KEYWARE TECH..

4. BENFICA (SLBEN.LS)

-6.06% Price Change

Sport Lisboa e Benfica – Futebol, SAD operates a sports club in Portugal. The company was founded in 1904 and is headquartered in Lisbon, Portugal. Sport Lisboa e Benfica – Futebol, SAD operates as a subsidiary of Sport Lisboa e Benfica SGPS SA.

PSI ended the session with BENFICA dropping 6.06% to €3.10 on Thursday while PSI slid 0.36% to €6,522.65.

Earnings Per Share

As for profitability, BENFICA has a trailing twelve months EPS of €1.54.

PE Ratio

BENFICA has a trailing twelve months price to earnings ratio of 2.01. Meaning, the purchaser of the share is investing €2.01 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.79%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 14.7%, now sitting on 195.8M for the twelve trailing months.

Volume

Today’s last reported volume for BENFICA is 1271 which is 43.66% below its average volume of 2256.

Yearly Top and Bottom Value

BENFICA’s stock is valued at €3.10 at 22:40 EST, way under its 52-week high of €3.99 and way higher than its 52-week low of €2.62.

More news about BENFICA.

5. NYXOAH (NYXH.BR)

-5.93% Price Change

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with NYXOAH dropping 5.93% to €6.66 on Thursday while BEL 20 rose 0.1% to €3,919.21.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.5.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.72%.

Yearly Top and Bottom Value

NYXOAH’s stock is valued at €6.66 at 22:40 EST, way under its 52-week high of €17.60 and way higher than its 52-week low of €3.79.

Volatility

NYXOAH’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.85%, a negative 1.04%, and a positive 4.29%.

NYXOAH’s highest amplitude of average volatility was 3.85% (last week), 3.03% (last month), and 4.29% (last quarter).

More news about NYXOAH.

6. FLUXYS BELGIUM D (FLUX.BR)

-5.6% Price Change

Fluxys Belgium SA, an infrastructure company, engages in transmission and storage of natural gas in Belgium. It offers terminalling services for liquefied natural gas (LNG); and transmits natural gas to distribution system operators, power stations and industrial end-users in Belgium, as well as to transport natural gas to border points for transmission to other end-user markets in Europe. The company also provides storage services, which enables customers to use buffer capacity flexibly through underground storage facilities of gas in Loenhout, Belgium; and engages in sale of standard bundled packages, composed of injection, storage and withdrawing capacity. In addition, it offers unloading and related services including storage and regasification, which transform the liquid gas into gas that can be injected in the grid; loading services; and transhipment services comprising Ship-To-Ship and Ship-Storage-Ship. Further, the company is involved in the reinsurance business. Fluxys Belgium SA was founded in 1929 and is based in Brussels, Belgium. Fluxys Belgium SA is a subsidiary of Fluxys SA.

BEL 20 ended the session with FLUXYS BELGIUM D falling 5.6% to €16.00 on Thursday while BEL 20 jumped 0.1% to €3,919.21.

Earnings Per Share

As for profitability, FLUXYS BELGIUM D has a trailing twelve months EPS of €1.1.

PE Ratio

FLUXYS BELGIUM D has a trailing twelve months price to earnings ratio of 14.55. Meaning, the purchaser of the share is investing €14.55 for every euro of annual earnings.

Volume

Today’s last reported volume for FLUXYS BELGIUM D is 9872 which is 125.59% above its average volume of 4376.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FLUXYS BELGIUM D’s stock is considered to be overbought (>=80).

Volatility

FLUXYS BELGIUM D’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.52%, a negative 1.02%, and a positive 1.44%.

FLUXYS BELGIUM D’s highest amplitude of average volatility was 1.52% (last week), 1.48% (last month), and 1.44% (last quarter).

More news about FLUXYS BELGIUM D.

7. ALAN ALLMAN (AAA.PA)

-5.39% Price Change

Alan Allman Associates, together with its subsidiaries, engages in the provision of consulting services in Canada, France, Belgium, Luxembourg, Switzerland, and Singapore. The company offers technology consulting in the areas, including cybersecurity, cloud, data management, digitalization of tools and processes, etc.; strategy and management consulting comprising risk management, commercial intelligence, market finance, process management, change management, etc.; and industrial transformation consulting, such as purchasing and supply chain issues, relocation, cost reduction, project management, materials, process consulting, etc. The company was incorporated in 1954 and is based in Issy-les-Moulineaux, France.

CAC 40 ended the session with ALAN ALLMAN sliding 5.39% to €7.90 on Thursday while CAC 40 dropped 1.03% to €7,530.72.

Earnings Per Share

As for profitability, ALAN ALLMAN has a trailing twelve months EPS of €0.19.

PE Ratio

ALAN ALLMAN has a trailing twelve months price to earnings ratio of 41.58. Meaning, the purchaser of the share is investing €41.58 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.5%.

Volatility

ALAN ALLMAN’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.02%, a negative 0.42%, and a positive 2.61%.

ALAN ALLMAN’s highest amplitude of average volatility was 2.90% (last week), 2.34% (last month), and 2.61% (last quarter).

Moving Average

ALAN ALLMAN’s worth is way under its 50-day moving average of €9.88 and way below its 200-day moving average of €10.73.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ALAN ALLMAN’s stock is considered to be oversold (<=20).

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 0.05 and the estimated forward annual dividend yield is 0.45%.

More news about ALAN ALLMAN.

8. PCI BIOTECH HOLD (PCIB.OL)

-3.68% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD dropping 3.68% to €1.83 on Thursday while Oslo Børs Benchmark Index_GI rose 0.47% to €1,415.84.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.54.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.

More news about PCI BIOTECH HOLD.

9. RAMADA (RAM.LS)

-3.67% Price Change

Ramada Investimentos e Industria, S.A. primarily operates in the steel and wire drawing business in Portugal and internationally. The company operates through Industry and Real Estate segments. It offers steel for use in the construction of machines and components; and production of tools, including dies, cutters, and moulds for industrial markets, such as plastic mold manufacturing, automotive industry components, capital goods, and components for household appliances and electronics. The company also manufactures and sells steel wires for the industrial, agriculture, and civil construction industries. In addition, it manages and leases real estate properties comprising forestry assets; and manages financial investments. The company was formerly known as F. Ramada Investimentos, SGPS, S.A. Ramada Investimentos e Industria, S.A. was founded in 1935 and is headquartered in Porto, Portugal.

PSI ended the session with RAMADA dropping 3.67% to €6.30 on Thursday while PSI slid 0.36% to €6,522.65.

Earnings Per Share

As for profitability, RAMADA has a trailing twelve months EPS of €0.36.

PE Ratio

RAMADA has a trailing twelve months price to earnings ratio of 17.5. Meaning, the purchaser of the share is investing €17.5 for every euro of annual earnings.

Moving Average

RAMADA’s value is below its 50-day moving average of €6.49 and under its 200-day moving average of €6.75.

Volatility

RAMADA’s last week, last month’s, and last quarter’s current intraday variation average was 0.47%, 0.11%, and 1.00%.

RAMADA’s highest amplitude of average volatility was 0.78% (last week), 0.96% (last month), and 1.00% (last quarter).

More news about RAMADA.

10. BERGENBIO (BGBIO.OL)

-3.6% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO falling 3.6% to €11.90 on Thursday while Oslo Børs Benchmark Index_GI jumped 0.47% to €1,415.84.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr67.

PE Ratio

BERGENBIO has a trailing twelve months price to earnings ratio of 0.18. Meaning, the purchaser of the share is investing kr0.18 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

BERGENBIO’s EBITDA is -2.91.

Yearly Top and Bottom Value

BERGENBIO’s stock is valued at kr11.90 at 22:40 EST, below its 52-week high of kr13.03 and way above its 52-week low of kr0.08.

Moving Average

BERGENBIO’s value is way above its 50-day moving average of kr0.13 and way higher than its 200-day moving average of kr4.18.

Volume

Today’s last reported volume for BERGENBIO is 133663 which is 68.72% below its average volume of 427442.

More news about BERGENBIO.

Stay up to date with our winners and losers daily report